Article
Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
PloS one - 1 Jan 2018
Mangia Alessandra, Losappio Ruggero, Cenderello Giovanni, Potenza Domenico, Mazzola Michele, De Stefano Giulio, Terreni Natalia, Copetti Massimiliano, Minerva Nicola, Piazzola Valeria, Bacca Donato, Palmieri Vincenzo, Sogari Fernando, Santoro Rosanna
Abstract excerpt
BACKGROUND: Treatment of GT3 remains challenging compared to other genotypes. AIMS: To explore real life SVR rates and to identify predictors of virological failure across the most recently used Direct acting antiviral (DAA) regimens in a large cohort of Italian patients with cirrhosis or advanced fibrosis (F3 or F4). METHODS: Between May 2015 and June 2017, the combinations of sofosbuvir (SOF) plus daclatasvir...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.